Clinical trial
A Phase 2, Open-label Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
Name
7791-003
Description
To evaluate the effect and safety of a switch from phosphate binders to KHK7791 to treat Hyperphosphatemia in patients on HD.
Trial arms
Trial start
2018-12-27
Estimated PCD
2019-11-26
Trial end
2019-11-26
Status
Completed
Phase
Early phase I
Treatment
KHK7791
KHK7791 30 mg, 20 mg ,10 mg or 5 mg tablets
Arms:
KHK7791
Other names:
Tenapanor
Size
67
Primary endpoint
Percentage of subjects who reduce the total number of taking phosphate binder tablets at the last assessment from baseline.
Week 26
Eligibility criteria
Inclusion Criteria:
* Stable chronic renal failure patients who have undergone hemodialysis 3 times per week for at least 12 weeks until screening examination.
* Met certain conditions for dialysis excluding Dry Weight (Dialysate, Dialyzer, Frequency of Dialysis per Week, Dialysis Time, Blood Flow Rate, and Dialysate and Substitution Fluid Flow Rate) 2 weeks before screening examination.
* Taking at least 2 tablets of phosphate binder 3 times per day. The prescribed dosage regimen should have been unchanged for the period from 2 weeks before screening examination through pre-enrollment.
* Serum phosphorus levels should be between 3.5 and 7.0 mg/dL (inclusive) at screening examination.
* If on any vitamin D or calcimimetics regimen, the dosage regimen should have been unchanged for the last 2 weeks before screening examination.
Exclusion Criteria:
* iPTH \> 600 pg/mL (should be based on the most recent value from patient's medical records before pre-enrollment)
* History of inflammatory bowel disease (IBD) or diarrhea predominant irritable bowel syndrome
* History of gastrectomy or enterectomy (excluding endoscopic resection and cecectomy) or having undergone gastrointestinal tract surgery within 3 months before screening examination.
* Severe heart disease (including congestive heart failure, defined as New York Heart Association \[NYHA\] cardiac functional classification of Class III or IV, and vascular lesions requiring hospitalization such as myocardial infarction), hepatic impairment (including AST/ALT ≥ 100 U/L before the start of observation period), or concurrent cirrhosis.
* Developed cerebrovascular disease (such as cerebral infarction and cerebral hemorrhage) or cardiovascular disease (such as acute myocardial infarction and unstable angina) requiring hospitalization within 6 months before screening examination.
* Uncontrollable hypertension or diabetes
* Scheduled for living donor kidney transplant, change in the mode of dialysis, home hemodialysis or plans to change the dialysis center (relocate to another hospital/clinic) during the study period.
* Any diagnosis of or treatment of malignancy within 5 years before screening examination (excluding basal cell carcinoma or surgically resected intraepithelial carcinoma of uterine cervix).
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 67, 'type': 'ACTUAL'}}
Updated at
2024-03-07
1 organization
1 product
1 indication
Organization
Kyowa KirinProduct
KHK7791Indication
Hyperphosphatemia